Naftzger J. Christopher 4
4 · Arbutus Biopharma Corp · Filed Feb 5, 2025
Insider Transaction Report
Form 4
Naftzger J. Christopher
General Counsel and CCO
Transactions
- Sale
Common Shares
2025-02-04$3.28/sh−11,333$37,206→ 86,244 total
Footnotes (2)
- [F1]Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on July 11, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units.
- [F2]Includes 1,214 and 1,263 shares acquired under the Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan on February 29, 2024 and August 30, 2024, respectively.